Compare Merck & Co., Inc. (MRK) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Newmont Corporation — how do they compare? Merck & Co., Inc. trades at $133.26 (market cap $327.94B), while Newmont Corporation trades at $116.4 (market cap $124.17B). The key difference: Merck & Co., Inc. is far larger — about 2.6× Newmont Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| MRK | NEM | |
|---|---|---|
Market Cap | $327.94B | $124.17B |
Sector | Health | Basic Materials |
52-Week High | $132.93 | $131.95 |
52-Week Low | $77.60 | $67.38 |
Enterprise Value | $374.70B | $120.76B |
Dividend Yield | 2.56% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples and competitive pressures. Analysts maintain a bullish consensus with a $140.58 price target, suggesting potential upside from current levels.
Newmont (NEM) trades at $118.52, up 1.07% on the day, with strong earnings beats in recent quarters and a bullish analyst consensus. Technical indicators show mixed signals with RSI near overbought levels but moving averages supporting an uptrend. Recent news highlights resolution of a Nevada dispute with Barrick and solid Q2 2026 results, reinforcing operational stability.
Outlook remains positive with a $133 consensus price target, driven by robust cash flow and gold price strength. Risks include potential cost pressures and reliance on commodity cycles, but institutional buying and high buy ratings suggest confidence in near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
